Novavax’s flu vaccine for older adults shows early promise against Sanofi’s Fluzone

Fierce Pharma -------- As the unsatisfactory performance posted by this season’s flu vaccines draws conversation around better prophylactic options, Novavax hopes to show that it’s new candidate could become one for older adults, who usually suffer the most from influenza. The company released positive early data from a phase 1/2 trial on its NanoFlu recombinant flu vaccine. It reported that the vaccine candidate elicited significantly higher antibody responses against multiple flu strains—especially the nasty H3N2 strains—in adults 60 of age or older compared to Sanofi Pasteur’s licensed Fluzone high-dose. To learn more click on the picture below to read the article.